Navigation Links
Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial
Date:9/27/2011

otential to revolutionise allergy therapy, and these recent results give us the confidence to proceed with the final phase II testing of our unique hay fever treatment."

About Circassia's allergy T-cell vaccines

Circassia is developing a range of allergy T-cell vaccines based on its proprietary ToleroMune® technology.  The company has successfully completed a number of phase II studies with its cat, house dust mite, ragweed and grass allergy therapies.  Clinical results show that short treatment regimes with Circassia's T-cell vaccines can greatly reduce patients' allergic responses, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated.  As a result, the treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities.  Over 150 million people suffer from allergic rhinitis in the US and Europe, and approximately 15% - 25% of people in these countries are sensitive to grass pollen.  As a result, the current allergy treatment market is valued at approximately $12 billion per year.  

About Circassia

Circassia was founded in 2006 by a team of highly experienced biotechnology scientists and entrepreneurs, and is chaired by the former Chairman of GlaxoSmithKline, Sir Richard Sykes.  The company is based in the UK on the Oxford Science Park, and in Hamilton, Canada, where its joint venture Adiga Life Sciences is located.  Its ToleroMune technology was developed originally by scientists at Imperial College, London.  Having successfully completed four fundraising rounds, Circassia has raised approximately £93 million ($159 million) and is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations and Invesco Perpetual.

Contacts
Steve Harris
CEO
Circassia
Tel: +44 (0)1865 784574

SOURCE Circassia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lactobacillus Beverage Confirmed to Reduce Fever Brought on by Acute Gastroenteritis Caused by Norovirus Infection
2. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
3. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
4. Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
5. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
6. Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
7. Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment
8. The New Face of Personalized Medicine: Targeting Disease Diagnostics and Treatments with Big Data Analytics: October 6, 2011, 1 PM EDT, Webinar
9. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
10. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
11. New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients Functionality and Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... CRANBURY, N.J., March 7, 2012 Palatin Technologies, Inc. (NYSE ... presenting at the 24th Annual ROTH OC Growth Stock Conference ... The conference will be held at the Ritz Carlton Laguna ... Ph.D., President and Chief Executive Officer of Palatin Technologies, will ...
... LONGNAN CITY, China, March 6, 2012   Apexigen, Inc., ... Biological Pharmaceutical Co., Ltd. (GDBP), which is listed ... they entered into a collaboration to grant an ... APX004 in China.   APX004 is a humanized monoclonal ...
... Drexel University,s Dr. Yury Gogotsi has given the engineering ... the electrodes of supercapacitors the low-cost, lightweight energy ... other applications. In a piece published in the March ... his collaborators from universities in France and England, take ...
Cached Biology Technology:Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 3Drexel's Gogotsi and team advance understanding of energy storage mechanisms in Nature Materials 2
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... LAS VEGAS , Oct. 7, 2013 ValidSoft, ... and transaction verification solutions, and a wholly owned subsidiary ... integrated its secure mobile commerce technology with Spindle,s new ... the Money2020 ( www.money2020.com ) conference being held from ...
... SAN DIEGO , Oct. 9, 2013  Biocom, the association ... community, today announced the endorsement of Nathan Fletcher ... . (Logo: http://photos.prnewswire.com/prnh/20130228/LA69104LOGO ) "A ... of the three major candidates.  Although all three would be ...
... SAN DIEGO , Oct. 14, 2013 Trovagene, ... cell-free molecular diagnostics, announced today that two abstracts (#B175 ... novel, non-invasive cancer mutation monitoring platform will be presented ... on Molecular Targets and Cancer Therapeutics in ...
Cached Biology News:ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 2ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 3ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 4ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 5Biocom Announces 2013 San Diego Mayoral Primary Endorsement 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 3
... 2500ml narrow mouth PYREX low form culture flask is ... to volume ratio. This flask has a heavy beaded ... marking spot. The neck O.D. is 38mm and takes ... use this flask on a heat source smaller than ...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... Pyronin Y is most widely used ... selectively and differentially stain nucleic acids ... dichromatic dye solution, Pyronin Y stains ... DNA green. Chem comp: ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Biology Products: